Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Englewood Lab

KOSDAQ:A950140
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A950140
KOSDAQ
₩77B
Market Cap
  1. Home
  2. KR
  3. Commercial Services
Company description

Englewood Lab, Inc. provides prescription, and research and development services for skin care industries in South Korea. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Englewood Lab has significant price volatility in the past 3 months.
A950140 Share Price and Events
7 Day Returns
27.8%
KOSDAQ:A950140
12.3%
KR Professional Services
1.8%
KR Market
1 Year Returns
-22.2%
KOSDAQ:A950140
-7%
KR Professional Services
-21.6%
KR Market
A950140 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Englewood Lab (A950140) 27.8% -15% -17.8% -22.2% -55.8% -
KR Professional Services 12.3% -10.2% -8.3% -7% 3.6% 10.7%
KR Market 1.8% -14.7% -18.6% -21.6% -19.6% -21.9%
1 Year Return vs Industry and Market
  • A950140 underperformed the Professional Services industry which returned -7% over the past year.
  • A950140 matched the Korea (Republic of) Market (-21.6%) over the past year.
Price Volatility
A950140
Industry
5yr Volatility vs Market
Related Companies

A950140 Value

 Is Englewood Lab undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Englewood Lab to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Englewood Lab.

KOSDAQ:A950140 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year KR Government Bond Rate 3.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for KOSDAQ:A950140
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year KR Govt Bond Rate 3.4%
Equity Risk Premium S&P Global 5.4%
Professional Services Unlevered Beta Simply Wall St/ S&P Global 0.77
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.768 (1 + (1- 21%) (40.72%))
1.01
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.01
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.43% + (1.01 * 5.44%)
8.93%

Discounted Cash Flow Calculation for KOSDAQ:A950140 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Englewood Lab is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

KOSDAQ:A950140 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (KRW, Millions) Source Present Value
Discounted (@ 8.93%)
2020 1,421.23 Est @ 50.55% 1,304.78
2021 1,938.79 Est @ 36.42% 1,634.09
2022 2,452.97 Est @ 26.52% 1,898.05
2023 2,933.59 Est @ 19.59% 2,083.95
2024 3,366.13 Est @ 14.74% 2,195.29
2025 3,748.19 Est @ 11.35% 2,244.16
2026 4,084.55 Est @ 8.97% 2,245.17
2027 4,383.16 Est @ 7.31% 2,211.90
2028 4,652.58 Est @ 6.15% 2,155.48
2029 4,900.64 Est @ 5.33% 2,084.37
Present value of next 10 years cash flows ₩20,057.00
KOSDAQ:A950140 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ₩4,900.64 × (1 + 3.43%) ÷ (8.93% – 3.43%)
₩92,241.86
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₩92,241.86 ÷ (1 + 8.93%)10
₩39,232.93
KOSDAQ:A950140 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₩20,057.00 + ₩39,232.93
₩59,289.93
Equity Value per Share
(KRW)
= Total value / Shares Outstanding
= ₩59,289.93 / 19.87
₩2984.21
KOSDAQ:A950140 Discount to Share Price
Calculation Result
Value per share (KRW) From above. ₩2,984.21
Current discount Discount to share price of ₩3,890.00
= -1 x (₩3,890.00 - ₩2,984.21) / ₩2,984.21
-30.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Englewood Lab is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Englewood Lab's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Englewood Lab's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KOSDAQ:A950140 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in KRW ₩117.00
KOSDAQ:A950140 Share Price ** KOSDAQ (2020-04-06) in KRW ₩3890
Korea (Republic of) Professional Services Industry PE Ratio Median Figure of 11 Publicly-Listed Professional Services Companies 12.48x
Korea (Republic of) Market PE Ratio Median Figure of 1,313 Publicly-Listed Companies 12.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Englewood Lab.

KOSDAQ:A950140 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KOSDAQ:A950140 Share Price ÷ EPS (both in KRW)

= 3890 ÷ 117.00

33.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Englewood Lab is overvalued based on earnings compared to the KR Professional Services industry average.
  • Englewood Lab is overvalued based on earnings compared to the Korea (Republic of) market.
Price based on expected Growth
Does Englewood Lab's expected growth come at a high price?
Raw Data
KOSDAQ:A950140 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 33.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Professional Services Industry PEG Ratio Median Figure of 55 Publicly-Listed Professional Services Companies 1.14x
Korea (Republic of) Market PEG Ratio Median Figure of 356 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Englewood Lab, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Englewood Lab's assets?
Raw Data
KOSDAQ:A950140 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in KRW ₩3,404.66
KOSDAQ:A950140 Share Price * KOSDAQ (2020-04-06) in KRW ₩3890
Korea (Republic of) Professional Services Industry PB Ratio Median Figure of 12 Publicly-Listed Professional Services Companies 1.1x
Korea (Republic of) Market PB Ratio Median Figure of 1,958 Publicly-Listed Companies 0.84x
KOSDAQ:A950140 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KOSDAQ:A950140 Share Price ÷ Book Value per Share (both in KRW)

= 3890 ÷ 3,404.66

1.14x

* Primary Listing of Englewood Lab.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Englewood Lab is overvalued based on assets compared to the KR Professional Services industry average.
X
Value checks
We assess Englewood Lab's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Professional Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Professional Services industry average (and greater than 0)? (1 check)
  5. Englewood Lab has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

A950140 Future Performance

 How is Englewood Lab expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Englewood Lab has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.1%
Expected Professional Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Englewood Lab expected to grow at an attractive rate?
  • Unable to compare Englewood Lab's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Englewood Lab's earnings growth to the Korea (Republic of) market average as no estimate data is available.
  • Unable to compare Englewood Lab's revenue growth to the Korea (Republic of) market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KOSDAQ:A950140 Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Professional Services Industry Earnings Growth Rate Market Cap Weighted Average 18.1%
Asia Professional Services Industry Revenue Growth Rate Market Cap Weighted Average 10.6%
Korea (Republic of) Market Earnings Growth Rate Market Cap Weighted Average 27.8%
Korea (Republic of) Market Revenue Growth Rate Market Cap Weighted Average 6.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KOSDAQ:A950140 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in KRW Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KOSDAQ:A950140 Past Financials Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income *
2019-12-31 133,317 12,116 2,269
2019-09-30 126,613 10,298 -4,106
2019-06-30 136,254 1,409 -650
2019-03-31 125,828 -4,718 -5,351
2018-12-31 118,766 -9,368 -5,899
2018-09-30 112,935 -11,128 -4,124
2018-06-30 94,598 -10,929 -12,425
2018-03-31 91,216 -12,338 -15,941
2017-12-31 87,135 -8,981 -13,878
2017-09-30 84,174 -6,358 -11,583
2017-06-30 86,487 -5,043 -7,618
2017-03-31 83,275 -2,861 516

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Englewood Lab is high growth as no earnings estimate data is available.
  • Unable to determine if Englewood Lab is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KOSDAQ:A950140 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Englewood Lab Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A950140 Past Financials Data
Date (Data in KRW Millions) EPS *
2019-12-31 117.00
2019-09-30 -204.81
2019-06-30 -32.41
2019-03-31 -267.73
2018-12-31 -297.00
2018-09-30 -215.04
2018-06-30 -645.41
2018-03-31 -822.44
2017-12-31 -712.00
2017-09-30 -673.04
2017-06-30 -487.94
2017-03-31 36.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Englewood Lab will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Englewood Lab's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Englewood Lab's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Commercial Services companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Englewood Lab's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Englewood Lab has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

A950140 Past Performance

  How has Englewood Lab performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Englewood Lab's growth in the last year to its industry (Professional Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Englewood Lab's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Englewood Lab has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Englewood Lab has become profitable in the last year making it difficult to compare the KR Professional Services industry average.
Earnings and Revenue History
Englewood Lab's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Englewood Lab Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A950140 Past Revenue, Cash Flow and Net Income Data
Date (Data in KRW Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 133,316.92 2,268.54 17,638.16 37.58
2019-09-30 126,613.06 -4,106.01 17,587.02 -89.88
2019-06-30 136,253.78 -649.79 17,242.65 -65.19
2019-03-31 125,827.78 -5,350.79 18,281.86 -55.16
2018-12-31 118,766.18 -5,898.85 18,755.63 66.77
2018-09-30 112,935.41 -4,123.58 21,391.81 -1,365.24
2018-06-30 94,598.26 -12,424.95 22,357.50 -705.44
2018-03-31 91,216.03 -15,940.65 21,783.75 64.50
2017-12-31 87,135.46 -13,877.93 20,614.79
2017-09-30 84,173.84 -11,583.28 16,980.79 1,636.92
2017-06-30 86,487.14 -7,618.43 15,515.24 913.27
2017-03-31 83,275.27 516.02 13,669.40 32.30
2016-12-31 79,182.41 -283.73 12,642.43
2015-12-31 143,135.66 13,267.16 18,590.00
2014-12-31 38,994.82 4,395.08 5,484.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Englewood Lab has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Englewood Lab used its assets less efficiently than the KR Professional Services industry average last year based on Return on Assets.
  • Englewood Lab's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Englewood Lab's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Professional Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Englewood Lab has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

A950140 Health

 How is Englewood Lab's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Englewood Lab's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Englewood Lab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Englewood Lab's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Englewood Lab's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Englewood Lab Company Filings, last reported 3 months ago.

KOSDAQ:A950140 Past Debt and Equity Data
Date (Data in KRW Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 61,125.07 25,275.66 5,461.31
2019-09-30 62,365.62 25,574.57 4,486.63
2019-06-30 59,859.72 25,730.33 2,068.95
2019-03-31 57,242.48 24,970.33 731.64
2018-12-31 56,705.44 27,188.24 1,105.68
2018-09-30 62,079.82 25,109.50 626.43
2018-06-30 58,791.09 22,528.65 1,817.08
2018-03-31 59,175.58 22,725.68 2,418.13
2017-12-31 60,330.86 18,469.48 7,035.12
2017-09-30 68,272.06 16,093.59 10,071.12
2017-06-30 72,209.16 15,116.25 15,568.23
2017-03-31 69,959.66 0.00 22,271.81
2016-12-31 74,811.00 0.00 30,806.12
2015-12-31 26,653.87 11,078.03 870.59
2014-12-31 6,456.57 4,820.17 495.42
  • Englewood Lab's level of debt (41.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (74.3% vs 41.4% today).
  • Debt is well covered by operating cash flow (47.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 6.8x coverage).
X
Financial health checks
We assess Englewood Lab's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Englewood Lab has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

A950140 Dividends

 What is Englewood Lab's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Englewood Lab dividends.
If you bought ₩2,000 of Englewood Lab shares you are expected to receive ₩0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Englewood Lab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Englewood Lab's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KOSDAQ:A950140 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Korea (Republic of) Professional Services Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 1.5%
Korea (Republic of) Market Average Dividend Yield Market Cap Weighted Average of 912 Stocks 2.9%
Korea (Republic of) Minimum Threshold Dividend Yield 10th Percentile 0.6%
Korea (Republic of) Bottom 25% Dividend Yield 25th Percentile 1.3%
Korea (Republic of) Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Englewood Lab has not reported any payouts.
  • Unable to verify if Englewood Lab's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Englewood Lab's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Englewood Lab has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Englewood Lab's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Englewood Lab afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Englewood Lab has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

A950140 Management

 What is the CEO of Englewood Lab's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Englewood Lab has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₩) Value (₩)
X
Management checks
We assess Englewood Lab's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Englewood Lab has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

A950140 News

Simply Wall St News

A950140 Company Info

Description

Englewood Lab, Inc. provides prescription, and research and development services for skin care industries in South Korea. It offers product testing, quality management, manufacturing and production, and process development services. The company is headquartered in Englewood, New Jersey.

Details
Name: Englewood Lab, Inc.
A950140
Exchange: KOSDAQ
Founded:
₩77,285,998,740
19,867,866
Website: http://englewoodlab.co.kr
Address: Englewood Lab, Inc.
88 West Sheffield Avenue,
Englewood,
New Jersey, 07631,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KOSDAQ A950140 Common Stock KOSDAQ KR KRW 14. Oct 2016
Number of employees
Current staff
Staff numbers
0
Englewood Lab employees.
Industry
Research and Consulting Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 16:53
End of day share price update: 2020/04/06 00:00
Last earnings filing: 2020/02/29
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.